AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 261 min read$GSK

Key facts: GSK plc Sponsored ADR Q3 Oct28; BEHOLD; Mo-Rez ORR 62%

GSK (Sponsored ADR) is set to report Q3 2026 results on Oct 28, with expected revenue of ~$11.6B (up 0.7% YoY) and EPS of $1.33. The mean 12-month price target is $58.43. Additionally, GSK's BEHOLD program and Mo-Rez phase I trial in ovarian cancer showed an ORR of 62% and a median PFS of 11.1 months, with data to be presented at ESMO Congress 2026.

Original reporting
tradingview.com
Published Oct 26, 2026, 8:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 8:12 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Key facts: GSK plc Sponsored ADR Q3 Oct28; BEHOLD; Mo-Rez ORR 62% — source image
Source · tradingview.com
Decision brief

The 30-second read

$GSKBullishHigh
01

Why it matters

The earnings beat and 62% ORR in a hard‑to‑treat cancer cohort could drive short‑term buying pressure and longer‑term valuation uplift.

02

Market read

First‑time earnings and trial data for a large‑cap pharma make this a high‑value trading catalyst.

03

What to watch

Potential regulatory scrutiny of trial design and upcoming competition in ovarian‑cancer therapies.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

GSK's Q3 earnings and early‑stage oncology trial results were released on Oct 28, providing fresh financial and clinical information.

Company-level read

Ticker impact

$GSKBullishHigh confidence
Context

GSK reported Q3 2026 earnings with revenue $11.6B, EPS $1.33, and disclosed BEHOLD-1 phase I data showing 62% ORR in ovarian cancer.

Expected impact

likely upside as market prices in earnings beat and promising trial data

Evidence & confidence

Both earnings and clinical data are first‑time disclosures for this quarter, providing fresh material for traders.

Market effects

Sector

Biopharma sector may see broader rally on positive oncology data.

Regional

UK and US markets could react to GSK's earnings and trial results.

Global

Large‑cap pharma news can influence global health‑care indices.

Counterpoint

What could challenge this read

If trial data does not translate to later‑stage success, the stock could face disappointment after an initial bump.

Key entities

  • company
    GSK plc

    British‑American pharmaceutical giant reporting Q3 results and trial data.

Read at source← All news

Related articles

OCT 26
$GSKMed

GSK: AZUR-1 Data Demonstrates Potential Of Jemperli

GSK reported positive interim results from the phase II AZUR-1 trial for Jemperli, showing 76% of patients achieved complete response. Additionally, updated data from the phase I BEHOLD-1 trial for Mo-Rez in platinum-resistant ovarian cancer showed a 62% objective response rate and 11.1 months of progression-free survival. GSK shares closed at 1,893.28 pence on the LSE.

rttnews.com1 min
OCT 26
$GSKMedAI 9/10

GSK cancer drug clears rectal tumours in 76% of patients in trial, data shows

GSK (LON:GSK) reported that its immunotherapy Jemperli cleared tumors completely in 76% of patients with a specific type of rectal cancer in a phase II trial. The trial met its main goal, with 47% of evaluable patients showing a complete response lasting 12 months. GSK also reported positive results for its experimental antibody-drug conjugate Mo-Rez in ovarian cancer, with a 62% response rate.

investing.com2 min
OCT 24
$GSKMedAI 8/10

ESMO26: Evidence for GSK's mo-rez builds in ovarian cancer

GSK's BEHOLD-1 study of mo-rez in platinum-resistant ovarian cancer showed a 62% ORR, 12.2-month median duration of response, and 11.1-month median PFS. Safety data was consistent with prior studies. GSK is accelerating development with five ongoing pivotal trials. According to GSK, the drug is licensed from Hansoh, with deals potentially worth up to $3.28 billion.

pharmaphorum.com2 min